SCHEMBL9938004

SCHEMBL9938004

CCOC(=O)c1c(C)[nH]c2cc(F)ccc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.60
MAPT P10636 4/20 0.58
PKM P14618 1/20 0.58
LMNA P02545 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
HPGD P15428 1/20 0.52
TSHR P16473 1/20 0.52
MAPK1 P28482 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
ALOX15 P16050 4/20 0.52
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
ALDH1A1 P00352 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
ALOX5 P09917 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9937467 0.89 GAA (0.72) GAAMAPTPKMLMNAL3MBTL1
SCHEMBL3004096 0.85 NR4A2 (0.63) GAAMAPTLMNAMEN1KMT2A
SCHEMBL25944684 0.83 MAPT (0.65) GAAMAPTPKMLMNAL3MBTL1
SCHEMBL23606247 0.83 GAA (0.60) GAAMAPTPKMLMNAL3MBTL1
SCHEMBL16344846 0.83 ALOX15 (0.70) GAAMAPTPKMLMNAL3MBTL1
SCHEMBL31486013 0.81 ALOX15 (0.46) GAAMAPTPKMMEN1KMT2A
SCHEMBL16344594 0.81 PTGS1 (0.60) GAAMAPTPKMLMNAL3MBTL1
SCHEMBL25169884 0.80 PTGS1 (0.55) GAAMAPTLMNAMEN1KMT2A
SCHEMBL3003836 0.80 PTGS1 (0.55) GAAMAPTPKMLMNAMEN1
SCHEMBL2885446 0.79 NR4A2 (0.71) GAAMAPTPKMLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023080193-A1 METHOD FOR PRODUCING INDOLE COMPOUND 日産化学株式会社 2023-05-11 WO disclosed
US-8993523-B2 Dimeric IAP inhibitors NOVARTIS AG (CH) 2015-03-31 US disclosed
US-20130309247-A1 DIMERIC IAP INHIBITORS NOVARTIS AG (CH) 2013-11-21 US disclosed
EP-2651919-A1 DIMERIC IAP INHIBITORS Novartis AG (CH) 2013-10-23 EP disclosed
WO-2012080271-A1 DIMERIC IAP INHIBITORS NOVARTIS AG (CH) 2012-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130309247-A1 DIMERIC IAP INHIBITORS XIAP, BIRC5, BIRC2 GAA 1947/4885MAPT 1235/4885PKM 2627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.